American association of clinical endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children - 2003 update

Endocrine Practice

Volumn 9, Issue 1, 2003, Pages 65-76

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GROWTH HORMONE; SOMATOMEDIN C;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; BONE REMODELING; CARDIOVASCULAR RISK; CHILD; CLINICAL PRACTICE; CREUTZFELDT JAKOB DISEASE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; GLUCOSE HOMEOSTASIS; GROWTH HORMONE DEFICIENCY; GROWTH RETARDATION; HUMAN; LIPOLYSIS; MEDICAL SOCIETY; MORTALITY; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; SHORT STATURE; TURNER SYNDROME;

EID: 0037821688     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Baum HB, Biller BM, Finkelstein JS, et al. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency: a randomized, placebo-controlled trial. Ann Intern Med. 1996;125:883-890.
2. Sesmilo G, Biller BM, Llevadot J, et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency: a randomized, controlled clinical trial. Ann Intern Med. 2000;133:111-122.
3. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 1990;336: 285-288.
4. Bulow B, Hagmar L, Mikoczy Z, Nordstrom CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf). 1997;46:75-81.
5. Nilsson B, Gustavasson-Kadaka E, Bengtsson BA, Jonsson B. Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality. J Clin Endocrinol Metab. 2000;85:1420-1425.
6. Tomlinson JW, Holden N, Hills RK, et al (West Midlands Prospective Hypopituitary Study Group). Association between premature mortality and hypopituitarism. Lancet. 2001;357:425-431.
7. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab. 1998;83:379-381.
8. Vance ML. Growth hormone: non-growth promoting uses in humans. Adv Endocrinol Metab. 1992;3:259-269.
9. Janssen YJ, Frolich M, Roelfsema F. A low starting dose of Genotropin in growth hormone-deficient adults. J Clin Endocrinol Metab. 1997;82:129-135.
10. Cook DM, Ludlam WH, Cook MB. Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults. J Clin Endocrinol Metab. 1999;84:3956-3960.
11. Amato G, Carella C, Fazio S, et al. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab. 1993;77:1671-1676.
12. Bengtsson BA, Eden S, Lonn L, et al. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab. 1993;76:309-317.
13. Carroll PV, Christ ER, Bengtsson BA, et al (Growth Hormone Research Society Scientific Committee). Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. J Clin Endocrinol Metab. 1998;83:382-395.
14. de Boer H, van der Veen EA. Why retest young adults with childhood-onset growth hormone deficiency? J Clin Endocrinol Metab. 1997;82:2032-2036.
15. Ion A, Crosby AH, Kremer H, et al. Detailed mapping, mutation analysis, and intragenic polymorphism identification in candidate Noonan syndrome genes MYL2, DCN, EPS8, and RPL6. J Med Genet. 2000;37:884-886.
16. GH Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. J Clin Endocrinol Metab. 2000;85:3990-3993.
17. Guidelines for the use of growth hormone in children with short stature: a report by the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. J Pediatr. 1995;127:857-867.
18. Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J (Genentech, Inc., Cooperative Study Group). High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. J Clin Endocrinol Metab. 2000;85:3653-3660.
19. Ranke MB, Saenger P. Turner's syndrome. Lancet. 2001; 358:309-314.
20. Saenger P, Wikland KA, Conway GS, et al. Recommendations for the diagnosis and management of Turner syndrome. J Clin Endocrinol Metab. 2001;86:3061-3069.
21. Toenshoff B, Mehls O. Growth retardation in children with chronic renal insufficiency: current aspects of pathophysiology and treatment. J Nephrol. 1995;8:133-142.
22. Fine RN, Kohaut EC, Brown D, Perlman AJ (Genentech Cooperative Study Group). Growth after recombinant human growth hormone treatment in children with chronic renal failure: report of a multicenter randomized double-blind placebo-controlled study. J Pediatr. 1994;12:374-382.
23. de Zegher F, Albertsson-Wikland K, Wollmann HA, et al. Growth hormone treatment of short children born small for gestational age: growth responses with continuous and discontinuous regimens over 6 years. J Clin Endocrinol Metab. 2000;85:2816-2821.
24. Sas T, de Waal W, Mulder P, et al. Growth hormone treatment in children with short stature born small for gestational age: 5-year results of a randomized, double-blind, dose-response trial. J Clin Endocrinol Metab. 1999;84: 3064-3070.
25. Sas T, Mulder P, Hokken-Koelega A. Body composition, blood pressure, and lipid metabolism before and during long-term growth hormone (GH) treatment in children with short stature born small for gestational age either with or without GH deficiency. J Clin Endocrinol Metab. 2000;85:3786-3792.
26. Burman P, Ritzen EM, Lindgren AC. Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH. Endocr Rev. 2001;22:787-799.
27. Ruokonen E, Takala J. Dangers of growth hormone therapy in critically ill patients. Ann Med. 2000;32:317-322.
28. Takala J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med. 1999;341:785-792.
29. Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. J Clin Endocrinol Metab. 2001;86:1868-1870.
30. Rosen T, Johannsson G, Johansson JO, Bengtsson BA. Consequences of growth hormone deficiency in adults and the benefits and risks of recombinant human growth hormone treatment: a review paper. Horm Res. 1995;43: 93-99